Evotec (NASDAQ:EVO) Posts Earnings Results, Misses Estimates By $0.06 EPS

Evotec (NASDAQ:EVO) announced its quarterly earnings data on Wednesday. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.06), FiscalAI reports. The company had revenue of $297.02 million for the quarter, compared to the consensus estimate of $276.94 million. Evotec had a negative net margin of 21.24% and a negative return on equity of 18.20%.

Here are the key takeaways from Evotec’s conference call:

• Just Evotec Biologics pivoted to an asset‑light, technology‑enablement model highlighted by the $650m Sandoz agreement, an approximately €65m Q4 license contribution and 39.8% full‑year revenue growth, positioning JAB as a higher‑margin growth pillar.
• The Horizon transformation targets structural run‑rate savings of about €75m by end‑2027 (with ~20–30% realized in 2026), plus consolidation to 10 sites and commercial upgrades designed to lift adjusted EBITDA margin toward and beyond 20% by 2028.
• The Discovery & Preclinical Development (DMPD) segment saw continued softness—2025 revenues declined ~13.5% and segment adjusted EBITDA turned negative due to overcapacity—making DMPD a near‑term drag with recovery expected mainly in H2 2026.
• Evotec enters 2026 with a strong liquidity position (~€476m cash and no active covenants), but management’s 2026 guidance is cautious (group revenues €700–780m; adjusted EBITDA €0–40m), reflecting a transition year with execution and market‑recovery risk.

Evotec Stock Performance

Shares of NASDAQ:EVO traded up $0.12 on Wednesday, hitting $2.70. 85,451 shares of the company’s stock were exchanged, compared to its average volume of 137,482. Evotec has a 12 month low of $2.31 and a 12 month high of $4.80. The business’s 50 day simple moving average is $3.05 and its two-hundred day simple moving average is $3.32. The company has a quick ratio of 2.03, a current ratio of 2.12 and a debt-to-equity ratio of 0.48.

Institutional Trading of Evotec

Several institutional investors and hedge funds have recently made changes to their positions in EVO. Wellington Management Group LLP lifted its position in shares of Evotec by 25.7% during the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after purchasing an additional 367,545 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Evotec during the fourth quarter valued at $565,000. Millennium Management LLC purchased a new position in shares of Evotec during the fourth quarter valued at $317,000. Citadel Advisors LLC increased its stake in shares of Evotec by 186.1% during the third quarter. Citadel Advisors LLC now owns 96,045 shares of the company’s stock valued at $349,000 after buying an additional 62,471 shares during the period. Finally, OLD Mission Capital LLC purchased a new position in shares of Evotec during the fourth quarter valued at $158,000. 5.81% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on EVO. Berenberg Bank began coverage on Evotec in a research report on Tuesday, February 3rd. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Evotec has a consensus rating of “Hold” and a consensus price target of $7.00.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.